Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
BIOCRYST PHARMACEUTICALS INC (BCRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update"
07/11/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/03/2023 8-K Quarterly results
04/18/2023 8-K Quarterly results
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
01/09/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "BioCryst Announces Preliminary Full Year 2022 ORLADEYO® Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance",
"BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases"
12/15/2022 8-K Quarterly results
11/01/2022 8-K Quarterly results
09/14/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer"
08/25/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment, to the Contract between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services",
"U.S. Government Exercises Option to Purchase Additional RAPIVAB® from BioCryst for Pandemic Influenza Preparedness"
08/04/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/11/2022 8-K Regulation FD Disclosure  Interactive Data
04/08/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BioCryst Pauses Enrollment in BCX9930 Clinical Trials"
02/23/2022 8-K Quarterly results
Docs: "BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones"
02/22/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "BioCryst Begins Patient Enrollment in RENEW Proof-of-Concept Trial Evaluating BCX9930 for Patients with Renal Complement-mediated Diseases"
02/17/2022 8-K Regulation FD Disclosure  Interactive Data
02/08/2022 8-K Quarterly results
01/10/2022 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "BioCryst Announces Preliminary Full Year 2021 ORLADEYO® Net Revenue and Provides Full Year 2022 ORLADEYO Net Revenue and Peak Sales Guidance"
01/07/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH"
11/29/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "BioCryst Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH"
11/22/2021 8-K Credit agreement amendment
11/03/2021 8-K Quarterly results
Docs: "BioCryst Reports Third Quarter 2021 Financial Results and Upcoming Key Milestones"
09/20/2021 8-K Quarterly results
09/01/2021 8-K Quarterly results
08/26/2021 8-K Quarterly results
08/09/2021 8-K Quarterly results
08/05/2021 8-K Quarterly results
08/03/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/28/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "BioCryst Appoints Vincent Milano to Board of Directors"
06/03/2021 8-K Quarterly results
05/26/2021 8-K Quarterly results
05/12/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy